Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

18 Mar 2024

Abstract excerpt

BACKGROUND: Optimizing immune checkpoint inhibitor (ICI) therapy may require identification of co-targetable checkpoint pathways via immune profiling. Herein, we analyzed the transcriptomic expression and clinical correlates of V-domain immunoglobulin suppressor of T-cell activation (VISTA), a promising targetable checkpoint. PATIENTS AND METHODS: RNA sequencing was carried out on 514 tissues reflecting diverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38503143
DOI: 10.1016/j.esmoop.2024.102942

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Viewing the immune checkpoint VISTA: landscape and outcomes across cancersPMID 38503143Read ↗

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsSemantic proximity Read ↗

The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast CancerSemantic proximity Read ↗

PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcomeSemantic proximity Read ↗

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneitySemantic proximity Read ↗

Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.Semantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read ↗

Identification of a novel immune checkpoint molecule V‐set immunoglobulin domain‐containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Immune Checkpoints are Predominantly Co-Expressed by Clonally Expanded CD4+FoxP3+ Intratumoral T-cells in Primary Human CancersSemantic proximity Read ↗

TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancerSemantic proximity Read ↗

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapiesSemantic proximity Read ↗

VISTA expression and patient selection for immune-based anticancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.